Epivax Oncology focuses on developing precision cancer immunotherapies that are customized and specifically designed for each patient's tumors, leveraging the Ancer™ platform and advances in next generation sequencing. Epivax was founded by an internationally known woman scientist, and has the potential to make a significant impact in the treatment of all types of solid tumors.